Ziopharm Oncology (ZIOP)

Company Description

ZIOPHARM Oncology (ZIOP) is a second-generation gene therapy company focused on the development of new cancer treatments with a laser focus on the red-hot immune oncology (I/O) sector. ZIOP licensed its gene expression control technology from synthetic-biology innovator Intrexon for use in the development of DNA-based oncology treatments. Under an exclusive channel partner agreement, the two companies have collaborated to develop a tightly controlled system that injects a gene-expression package into tumors to express the anti-tumor cytokine interleukin-12 (IL-12), but only when patients take a pill that contains a ligand to activate the IL-12 gene. When the patient stops taking the pill, IL-12 expression stops, allowing for specific dosing for a set time. Expression is controlled by Intrexon’s proprietary biologic switch known as the RheoSwitch. The ability to administer or withdraw the pill to control gene expression is a key safety benefit.


1 First Avenue
Parris Building, #34
Navy Yard Plaza
Boston, MA 02129
United States

(617) 259-1970


Get BioInvest's perspective on Ziopharm's CEO

Latest Company News

A Look at 2 Trending Stocks: TC PipeLines, LP (TCP), ZIOPHARM Oncology, Inc ... Post Analyst - 4 hours ago Turning to ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP), its shares were trading at $6.3 a gain of $0.07, on the trading floor. How Analysts Feel About Ziopharm Oncology Incorporated (NASDAQ:ZIOP) After ... - WeeklyHub ZIOPHARM Oncology Inc. (ZIOP) Reaches $6.38 After 9.00% Up Move; Southeastern ... - Wolcott Daily [...]
Tue, Jun 27, 2017 5:26:00 PM, Continue reading at the source
Option Market Alert: ZIOPHARM Oncology Inc Implied Price Swing Hits An ... CML News - Jun 24, 2017 No Risk Alert Here: Before we dive into any analysis we simply note that ZIOPHARM Oncology Inc (NASDAQ:ZIOP) risk is neither elevated nor depressed. Just the Facts on ZIOPHARM Oncology, Inc. (ZIOP) - StockNewsJournal Earnings And Analyst Opinion Offer Spending Insights: ZIOPHARM Oncology, Inc ... - Post Analyst [...]
Sat, Jun 24, 2017 10:18:00 AM, Continue reading at the source
50 DMA for ZIOPHARM Oncology, Inc. (ZIOP) moves above 13-week low NY Stock News - Jun 21, 2017 The technicals for ZIOPHARM Oncology, Inc. (ZIOP) have taken shape, and with them a comprehensive picture has emerged. [...]
Wed, Jun 21, 2017 6:43:00 PM, Continue reading at the source
Bullish On Ziopharm Seeking Alpha - Jun 21, 2017 Ziopharm Oncology Inc. (NASDAQ:ZIOP) has been working on a gene treatment to fight GBM, specifically on patients with recurrent or progressive diagnoses. [...]
Wed, Jun 21, 2017 6:33:00 PM, Continue reading at the source
ZIOPHARM Oncology Inc (ZIOP) Soars 6.45% on June 20 Equities.com - Jun 20, 2017 ZIOPHARM Oncology Inc (ZIOP) had a good day on the market for Tuesday June 20 as shares jumped 6.45% to close at $5.78. About 2.29 million shares traded hands on 10,096 trades for the day, compared with an average daily volume of 1.38 million ... ZIOPHARM Oncology, Inc. (ZIOP) Closed at $5.78 - HugoPress [...]
Tue, Jun 20, 2017 9:30:00 PM, Continue reading at the source
Why Investors remained buoyant on: ZIOPHARM Oncology, Inc. (ZIOP), Union ... StockNewsJournal - Jun 14, 2017 ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) market capitalization at present is $799.48M at the rate of $5.54 a share. The firm's price-to-sales ratio was noted 119.78 in contrast with an overall industry average of 102.28. [...]
Wed, Jun 14, 2017 10:30:00 AM, Continue reading at the source
ZIOPHARM Oncology Announces Positive Updated Results of Ad-RTS-hIL-12 + ... GlobeNewswire (press release) - Jun 5, 2017 BOSTON, June 05, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced updated results from its Phase 1 multicenter study of Ad-RTS-hIL-12 + veledimex ... [...]
Mon, Jun 05, 2017 6:18:00 PM, Continue reading at the source
ZIOPHARM to Present at the Jefferies 2017 Global Healthcare Conference GlobeNewswire (press release) - Jun 2, 2017 BOSTON, June 02, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Laurence Cooper, M.D. [...]
Fri, Jun 02, 2017 10:52:00 AM, Continue reading at the source
How ZIOPHARM Oncology, Inc. (ZIOP) And Its Latest Technicals Are Playing Out NY Stock News - Jun 1, 2017 ZIOPHARM Oncology, Inc. (ZIOP) is now trading with a very clear set of technicals. Taken together they paint a very compelling picture of how investors and traders should be approaching ZIOP. [...]
Thu, Jun 01, 2017 3:00:00 PM, Continue reading at the source
ZIOPHARM Oncology, Inc. (ZIOP) Makes Compelling Case Using Its Technical Chart ... NY Stock News - May 29, 2017 ZIOPHARM Oncology, Inc. (ZIOP) has created a compelling message for traders in the most recent trading. That message has grown stronger as the technical chart setup has developed into a more composite picture for the stock. [...]
Mon, May 29, 2017 2:10:00 PM, Continue reading at the source